Analytical Data
-
Gene name
PTP-MEG2/PTPN9
- Application
-
Alternative Names
MEG2; Protein-tyrosine phosphatase MEG2; Tyrosine-protein phosphatase non-receptor type 9
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P43378
-
Expression Region
Gln289~Gln593
-
Molecular Weight
39kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTP-MEG2 (Protein Tyrosine Phosphatase Megakaryocyte-Erythroid-Generated 2) and PTPN9 are members of the protein tyrosine phosphatase (PTP) family, which play crucial roles in cellular signaling processes by regulating phosphorylation states of tyrosine residues on proteins. These enzymes are implicated in various physiological processes, including cell growth, differentiation, and immune responses. Dysregulation of PTPs is often associated with diseases, including cancer and autoimmune disorders. The study of PTP-MEG2 and PTPN9 allows researchers to understand their specific functions and regulatory mechanisms in greater detail. Recent studies have suggested that these phosphatases may influence hematopoiesis and immune cell functions, making them potential targets for therapeutic interventions. Recombinant proteins of PTP-MEG2 and PTPN9 provide valuable tools for investigating their enzymatic activities, substrate interactions, and cellular roles. By utilizing recombinant technology, researchers can produce these proteins in a controlled manner, facilitating biophysical and biochemical analyses that may reveal novel insights into their contributions to cellular dynamics and disease pathology. This research is critical for identifying new biomarkers and therapeutic targets in hematological malignancies and autoimmune diseases, potentially leading to the development of innovative treatments.
